Verici Dx (VRCI) Stock Overview
Together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
VRCI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Verici Dx plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0085 |
| 52 Week High | UK£0.065 |
| 52 Week Low | UK£0.0047 |
| Beta | 1.56 |
| 1 Month Change | 6.25% |
| 3 Month Change | 36.00% |
| 1 Year Change | -67.62% |
| 3 Year Change | -93.20% |
| 5 Year Change | -98.13% |
| Change since IPO | -97.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| VRCI | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -3.0% | -0.007% |
| 1Y | -67.6% | 16.0% | 15.7% |
Return vs Industry: VRCI underperformed the UK Biotechs industry which returned 16% over the past year.
Return vs Market: VRCI underperformed the UK Market which returned 15.7% over the past year.
Price Volatility
| VRCI volatility | |
|---|---|
| VRCI Average Weekly Movement | 16.6% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.9% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: VRCI's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: VRCI's weekly volatility has decreased from 22% to 17% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 15 | Sara Barrington | vericidx.com |
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and germline exomes; whole transcriptome, targeted RNASeq and ncRNAs, and functional binding multicell assay.
Verici Dx plc Fundamentals Summary
| VRCI fundamental statistics | |
|---|---|
| Market cap | UK£12.86m |
| Earnings (TTM) | -UK£5.69m |
| Revenue (TTM) | UK£1.43m |
Is VRCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRCI income statement (TTM) | |
|---|---|
| Revenue | US$1.91m |
| Cost of Revenue | US$352.00k |
| Gross Profit | US$1.56m |
| Other Expenses | US$9.18m |
| Earnings | -US$7.62m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.005 |
| Gross Margin | 81.60% |
| Net Profit Margin | -398.12% |
| Debt/Equity Ratio | 0% |
How did VRCI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 02:57 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Verici Dx plc is covered by 0 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.